Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5m per year in England (or £9,100 per 100,000 population). Etelcalcetide is a treatment option when treatment with a calcimimetic is indicated, but cinacalcet is not suitable. The population treated with etelcalcetide is estimated to be around 1,800 for England.

The list price of etelcalcetide has a discount that is commercial in confidence. Any enquiries from NHS organisations about the patient access scheme should be directed to Jean-Gabriele Castaigne on jcastaig@amgen.com or 01223 436439, or to Kawitha Helme on kvardeva@amgen.com or 01895 525515.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 28 June 2017